Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.